Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Investor Presentation (August 2016)
19 slides from Neurizon Therapeutics's investor presentation, August 2016
Slide 1: Investor Presentation August 2016
For personal use only ASX: PAA ACN 094 006 023 Investor Presentation August 2016
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the Co pa y . It does not purport to contain all the For personal use only information that a prospective investor may require in connection with any potential investment in the Company. You
Slide 3: Financial Snapshot
Financial Snapshot For personal use only ASX Code PAA Total Shares on Issue 92,503,645 Market Cap (at 8.5c per share) $8.5M Cash (last Qtr) $1.3M Debt (last Qtr)1 $500,000 Sales (est) $2.4M Data as of June 30, 2016 1 EFIC loan to Epichem ASX: PAA
Slide 4: Business Overview
Business Overview Proprietary Technology based on New Use of a registered drug– discovery of drug For personal use only new class of targeted therapy for cancer Lead product Monepantel-MPL, registered for Veterinary Use by Novartis Animal Health (anti-parasitic) Research Option Agreement with
Slide 5: Investment Highlights 2016-2017
Investment Highlights 2016-2017 Investor value inflection points based on: For personal use only • Phase II outcome man – Phase I complete and Phase II centres being identified • Phase II (VET) outcome canine – trials underway, Department of Veterinary Medicine of the University of Cambridge • Exerc
Slide 6: Key Drivers for Phase II in Man and Canines
Key Drivers for Phase II in Man and Canines • Phase I (MAN) demonstrated safety and activity in patients that failed all For personal use only sta dard of are 9 patie ts • Phase I (VET) demonstrated safety and activity in patients that failed all sta dard of are 11 patie ts • Combinations of Chemo a
Slide 7: Elevated p-RPS6KB1 is Associated with Poor Outcomes in Cancer
Elevated p-RPS6KB1(p70s6k) is Associated with Poor Outcomes in Cancer For personal use only High p-RPS6KB1 in patients with colorectal, lung, ovarian, pancreatic and hepatic cancers correlates with: • Resistance to therapy • Aggressive disease • Poor prognosis • High metastasis 1) Rapamune – sirolim
Slide 8: High s6k Correlates with Multiple Negative Outcomes
High s6k Correlates with Multiple Negative Outcomes For personal use only Two complexes of mTOR (mammalian target of rapamycin) High s6k (p70s6k) in mTORC1 mTORC2 patients correlates with: PRAS40 Protor mSin1 mTOR mTOR Raptor GβL Rictor GβL Resistance to therapy Deptor Deptor Aggressive disease
Slide 9: Suppression of p70s6k by MPL in Humans
Suppression of p70s6k by MPL in Humans For personal use only D e te r m in a tio n o f p -P 7 0 S 6 K in P B M C o f p a tie n ts tr e a te d w ith M P L D a y 1 b e fo re tre a tm e n t 100 D ay 3 ** * D ay 7 1 ** ** (% c o n tr o l) *** p -P 7 0 S 6 K 50 ****** **** 0 R 01 R 101 R 02 R 102 R 202 R
Slide 10: Suppression of p-4E-BP1 by MPL in Humans
Suppression of p-4E-BP1 by MPL in Humans For personal use only D e te r m in a tio n o f p -4 E -B P 1 in P B M C o f p a tie n ts tr e a te d w ith M P L D a y 1 b e fo re tre a tm e n t 150 D ay 3 D ay 7 1 (% c o n tr o l) p -4 E -B P 1 100 * * * 50 ** ** 0 R 01 R 101 R 02 R 102 R 202 P A0 8 1 Poo
Slide 11: Suppression of p70s6k and tumour size and increased QOL by MPL in Canines
Suppression of p70s6k and tumour size and increased QOL by MPL in Canines For personal use only p-p70s6k P - p 7 0ELISA S 6 K E in li s dog 1oPBMC a in d g PBMC p-p70s6k ELISA in dog 2 PBMC P - p 7 0 S 6 K E lis a in d o g (M o r t im e r C a m b e ll) P B M C Relapsed Lymphoma Relapsed Lymphoma 125
Slide 12: Canine Cancer Trial
Canine Cancer Trial Department of Veterinary Medicine, University of Cambridge For personal use only Aims: • Extend on Phase I canine cancer trial undertaken in Sydney which showed suppression of cancer marker p-Rps6kb1 • Demonstrate tumour regression or progression free survival • Outcome trigger f
Slide 13: Major palatability drawback of MPL now resolved
Major palatability drawback of MPL in human and canine trials now resolved For personal use only Compliance for more than 3 days of treatment in both man and canines was challenging in Phase I due to the remarkably foul taste of the MPL (Zolvix) liquid formulation manufactured by Novartis. GMP Refor
Slide 14: MPL is a New Targeted Therapy within the $100B Cancer Treatment Market
MPL is a New Targeted Therapy within the $100B Cancer Treatment Market 1 For personal use only Surgery Stem Cell Radiation Targeted Therapy $100B1 Typically small molecules or monoclonal antibodies Targeted Chemo Therapy MPL Hormonal 1 Reuters ASX: PAA 14
Slide 15: In Summary: MPL Achieved All Key Phase I Endpoints
In Summary MPL Achieved All Key Phase I Endpoints For personal use only 1. Safety – Excellent safety profile as predicted from pre- clinical models 2. Active dose – Identified dosage of MPL from effects on cancer markers in man 3. Efficacy – Determined efficacy by markers and effects on tumours (p70
Slide 16: In Summary: Phase II Performance supported by Preclinical and Phase I data
In Summary Phase II Performance supported by Preclinical and Phase I data pack For personal use only Considerable pre-clinical R&D package in cancer models Substantial third party pre-clinical package as MPL on market with global major (Novartis Animal Health) Activity in naturally occurring c
Slide 17: In Summary: MPL Already Approved for Veterinary Applications
In Summary MPL Already Approved for Veterinary Applications For personal use only Novartis Animal Health registered Zolvix (MPL) for the treatment of parasitic diseases in animals Extensive manufacturing and toxicology already established by global major pharma company Over 50 MPL analogues ar
Slide 18: Experienced Management
Experienced Management For personal use only Dr. Roger Aston, Executive Chairman Dr Aston is both a scientist and seasoned biotechnology entrepreneur, with a successful track record in both fields. Previously at Wellcome Research Laboratories, Peptech, Cambridge Antibody Technology, QinetiQ, pSivida
Slide 19: For personal use only
For personal use only SAM WRIGHT DR ROGER ASTON Director & Company Secretary [email protected] Executive Chairman [email protected] ASX: PAA Phone: 61 (0) 408 900 277 Phone: 61 (0) 402 762 204 ACN 094 006 19 023